Remote patient monitoring startup Sibel Health ended a $30 million C funding on Thursday, with a total funding of $63 million.
Founded in 2018, the company is a split of Northwestern University – with headquarters in the Chicago area and offices in San Diego and Seoul. Its mission is to make healthcare data more useful by developing wearable monitors for the entire clinical care continuum.
Sibel's remote vital monitoring platform, called Anne One, uses wearable sensors to capture patient vital signs, including skin and body temperature, heart rate, breathing rate, step count and body position. The overall goal of the platform is to provide accurate data that clinicians can use to make informed treatment decisions for patients.
The company's sensors are lightweight and have adhesives that allow them to stick to the skin comfortably while constantly monitoring patients. CEO Steve Xu noted that the technology has a “form of generalizing band-aids.”
“[The sensors] “Soft, flexible and stretchable, but can reproduce vital signs currently required to be hung on a wall on a wired ICU monitor,” he said.
Xu pointed out that comfort is the first because the remote monitoring system does not work unless the patient wants to wear it. Interviewed in 2022 Medcity NewsXu said Sibel’s focus on patient experience helps it stand out among other remote patient monitoring companies.
He added that the startup can ensure that patients have the data from the moment they see the adhesive that the nurse or doctor sees the final display.
In addition to its Series C financing round, Sibel announced its seventh FDA license. The decision enables clinicians to use alerts and alerts with the Anne One platform.
In Xu's eyes, all patients in the hospital should be continuously monitored.
“Most deaths in hospital settings do not occur in the ICU – they occur in general wards on unmonitored beds. By constantly monitoring patients, we have the opportunity to detect deterioration as early as possible and save lives,” he declared.
He also noted that the manual process of collecting vitality in an unsupervised bed can be time-consuming and frustrating—but Sibel’s wearables can free up time so they can practice on the top of their licenses.
Xu said that with new capital influx of capital, Sibel plans to accelerate commercial deployment of its sensors between providers and pharmaceutical companies in the United States and Europe.
Some of the company's clients include Abbvie, Northwestern Medicine and the Denmark capital region.
Photo: Phive2015, Getty Images
